EASD 2025 Learnings and Action from the Conference -

EASD 2025 was a great conference — I learned a lot, recorded some brilliant podcasts, and caught up with friends and colleagues. Here’s my comprehensive review.

First up, the upcoming podcasts recorded at EASD 2025:

Othmar Moser on the importance of activity and how to manage exercise – an absolute masterclass.
Partha Kar on the “Five to Drive” principles for implementing technology and driving change – learn how to be a change maker!
CGM regulation with Guido Freckmann and Stefan Prost, leads of the IFCC, on the path to an ISO 2030 – we need #CGMISO30
Peter Adolfsson on children with diabetes using technology and how to get whole teams aligned to drive services and international change – How to become a world-class service using sports psychology.

It was also great fun to hang out with my good buddy Amy Jolly, a specialist dietitian and technology lead at Salford, and a key member of the Diabetes Technology Network. A big thank you to her for the support in creating this content and consolidating the learning as we went along.

Executive Summary

EASD 2025 underscored two parallel truths: (1) technology is now the backbone of day-to-day diabetes care (Automated Insulin Delivery (AID), CGM, smart MDI); (2) without clear standards and regulation, we risk confusing people with diabetes, clinicians, and researchers. Across five days, four themes stood out:

Automated Insulin Delivery (AID) gets more capable — but user behaviours still matter.
Screening for early-stage T1D moving from “whether” to “how.”
CGM regulation: the push for higher, clearer minimum standards. See the CGM Guide for greater depth.
Glucose Level Lifestyle — nutrition, sleep, and exercise management.

1) Automated Insulin Delivery (AID)

MiniMed 780G: Evidence now extends to children, pregnancy, and T2D. In real-world cohorts, mean Time in Range (TIR) often exceeded 70% with hypoglycaemia <3%, showing that with good configuration, benefits are consistent across populations. See my AID systems review. However, it’s important to remember that the sensor used with the 780G has been shown to over-report TIR by about 8% and TITR by about 13%, which has fuelled urgent calls for standardisation of CGM accuracy evaluation.
Tandem Control-IQ (INRANGE): Two-year real-world data showed durable glycaemic benefit with mean TIR ~68–70%, A1C reduction of ~0.5%, and sustained improvement in quality-of-life metrics — a signal that benefits last beyond the honeymoon of adoption.
Smart MDI (InPen): In >5,000 users, responding to alerts (missed bolus/correction reminders) increased TIR into the 68–72% range without more hypoglycaemia. This highlights that behaviour + tech can rival pump outcomes for some.
Unannounced meals crossover: In a 20-participant trial, PID (780G) handled unannounced mixed meals with peak ~200 mg/dL, versus ~230 mg/dL for MPC (Control-IQ). Announced meals converged ~150–160 mg/dL.
RAPPID: Exercise study showing AID reduces but does not eliminate late-onset hypoglycaemia; TIR dipped most 3–15h post-activity.

Take-home: AID and smart pens improve outcomes, but “engage or lose” applies: alerts, meal announcements, and data reviews are not optional.

Forward-looking practice: Develop structured “fallback playbooks” for unannounced meals and standardised exercise protocols across AID platforms. This could evolve into a practical reference library for clinicians and people with diabetes.

2) Screening for Early-Stage Type 1 Diabetes

EDENT1FI: Home fingerstick kits + primary-care integration achieved high parental acceptability and linkage to follow-up, showing it’s feasible to move from trials to practice.
European consensus: Proposed structured schedules (e.g., relatives at 1–2 years, again at 4–5 years; autoimmune cohorts screened at diagnosis and periodically). This marks the first coordinated attempt to unify who, when, and how across Europe. This comes off the back of the Pre-stage 3 T1D Consensus in 2024

Take-home: Screening is moving from opportunistic to protocolised with home kits and reflex care pathways.

Forward-looking practice: We should aim to embed screening prompts into child health visits and autoimmune registries, while building GDPR-compliant registries that link positive screens to prevention trials and education.

3) CGM Regulation & Standards

Push to end “MARD-doping”: requiring accuracy testing across glucose ranges, activity states, and sites of wear.
Toward ISO CGM standards: A shared roadmap now exists, aligning EU requirements with FDA iCGM frameworks. This includes stratified accuracy claims and transparent reporting of adverse events. See the CGM Guide for greater depth.
Clinician note: document sensor model in records and interpret TIR in light of alignment (capillary vs venous). For example, 70% TIR on one sensor may equate to ~63% on another if calibration targets differ. Remember that the sensor used with the 780G has been shown to over-report TIR by about 8% and TITR by about 13%, which has fuelled urgent calls for standardisation of CGM accuracy evaluation.

Take-home: Without standardisation, 70% TIR ≠ 70% TIR across devices.

Forward-looking practice: Advocate for transparent accuracy dashboards, demand standardised targets (capillary alignment), and prepare clinicians with education modules so they can confidently interpret CGM metrics across devices.

4) Glucose Level Lifestyle

Sleep: Adults achieving 7–9h nightly sleep had mean glucose ~8.9 mmol/L vs 9.6–9.7 mmol/L for <7h sleepers, with TIR ~64% vs ~57%. This makes sleep a modifiable glycaemic lever.
Pregnancy & GDM: In GRACE, CGM use cut large-for-gestational-age births (3.5% vs 10.3%) and reduced NICU admissions. DipGluMo showed neutral results, highlighting that population and context matter.
Exercise: In structured + home settings, Libre 3 and Dexcom G7 outperformed Simplera during activity, with MedARD gaps widening most during exercise. Also see CGM and Exercise for T1D.

Action: Optimise lifestyle alongside tech: sleep routines, CGM in GDM care, and exercise-ready tactics.

Forward-looking practice: Future work should include structured sleep interventions for people with diabetes, integration of CGM into antenatal pathways worldwide, and robust exercise-phase sensor validation trials.

Clinician Checklist

AID setup: confirm ISF/ICR, enable meal prompts, set exercise presets.
Smart MDI: ensure alerts are active and users know how to respond.
Screening for T1D adopt home kits where possible.
CGM regulation awareness. See the CGM Guide for greater depth.

Othmar Moser on the importance of activity and how to manage exercise – an absolute masterclass.
Partha Kar on the “Five to Drive” principles for implementing technology and driving change – learn how to be a change maker!
CGM regulation with Guido Freckmann and Stefan Prost, leads of the IFCC, on the path to an ISO 2030 – we need #CGMISO30
Peter Adolfsson on children with diabetes using technology and how to get whole teams aligned to drive services and international change – How to become a world-class service using sports psychology.